Management of dyslipidemia in the metabolic syndrome

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 7, Issue 2, 2007, Pages 99-108

  Tan, Kathryn C B ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Dyslipidemia; Hypertriglyceridemia; Insulin resistance; Metabolic syndrome; Small dense LDL

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DOCOSAHEXAENOIC ACID; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL;

AGE DISTRIBUTION; ASIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET THERAPY; DIETARY REFERENCE INTAKE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DYSLIPIDEMIA; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOTHERAPY; MYOPATHY; NONHUMAN; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; RISK REDUCTION; SIDE EFFECT; WEIGHT REDUCTION;

EID: 34347394984     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152907780830860     Document Type: Review

References (113)

1. Isomaa, B.; Almgren, P.; Tuomi, T.; Forsen, B.; Lahti, K.; Nissen, M.; Taskinen, MR.; Groop, L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24, 683-689.
2. Lakka, H.M.; Laaksonen, D.E.; Lakka, T.A.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J.; Salonen, J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 2002, 288, 2709-2716.
3. Alberti, K.G.; Zimmet, P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med., 1998, 15, 539-553.
4. Balkau, B.; Charles, M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR), Diab. Med., 1999, 16, 442-443.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
6. Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin, B.A.; Gordon, D.J.; Krauss, R.M.; Savage, P.J.; Smith, S.C. Jr, Spertus, J.A.; Costa, F. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation, 2005, 112, 2735-2752.
7. Alberti, K.G.; Zimmet, P.; Shaw, J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med., 2006, 23, 469-480.
8. Ford, E.S.; Giles, W.H.; Dietz, W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 2002, 287, 356-359.
9. Alexander, C.M.; Landsman, P.B.; Teutsch, S.M.; Haffner, S.M.; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 2003, 52, 1210-1214.
10. Anand, S.S.; Yi, Q.; Gerstein, H.; Lonn, E.; Jacobs, R.; Vuksan, V.; Teo, K.; Davis, B.; Montague, P.; Yusuf, S.; Study of Health Assessment and Risk in Ethnic Groups; Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation, 2003, 108, 420-425.
11. Gu, D.; Reynolds, K.; Wu, X.; Chen, J.; Duan, X.; Reynolds, R.F.; Whelton, P.K.; He, J.; InterASIA Collaborative Group Prevalence of the metabolic syndrome and overweight among adults in China. Lancet, 2005, 365, 1398-1405.
12. Patel, A.; Huang, K.C.; Janus, E.D.; Gill, T.; Neal, B.; Suriyawongpaisal, P.; Wong, E.; Woodward, M.; Stolk, R.P. Is a single definition of the metabolic syndrome appropriate? A comparative study of the USA and Asia. Atherosclerosis, 2006, 184, 225-232.
13. Park, J.S.; Park, H.D.; Yun, J.W.; Jung, C.H.; Lee, W.Y.; Kim, S.W. Prevalence of the metabolic syndrome as defined by NCEP-ATP III among the urban Korean population. Korean J. Med., 2002, 63, 290-298.
14. Ko, G.T.; Chan, J.C.; Cockram, C.S.; Woo, J. Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese. Int. J. Obes. Relat. Metab. Disord., 1999, 23, 1136-1142.
15. Li, G.; Chen, X.; Jang, Y.; Wang, J.; Xing, X.; Yang, W.; Hu,Y. Obesity, coronary heart disease risk factors and diabetes in Chinese: an approach to the criteria of obesity in the Chinese population. Obes Rev., 2002, 3, 167-172.
16. WHO Expert Consultation, Appropriate body mass index for Asian populations and its implications for policy and intervention strategies, Lancet, 2004, 363, 157-163.
17. Wang, J.; Thornton, J.C.; Russell, M.; Burastero, S.; Heymsfield, S.; Pierson, R.N. Jr. Asians have lower body mass index (BMI) but higher percent body fat than do whites: comparisons of anthropometric measurements. Am. J. Clin. Nutr., 1994, 60, 23-28.
18. Deurenberg-Yap, M.; Chew, S.K.; Deurenberg, P. Elevated body fat percentage and cardiovascular risks at low body mass index levels among Singaporean Chinese, Malays and Indians. Obes. Rev., 2002, 3, 209-215.
19. He, M.; Tan, K.C.; Li, E.T.; Kung, A.W. Body fat determination by dual energy X-ray absorptiometry and its relation to body mass index and waist circumference in Hong Kong Chinese. Int. J. Obes. Relat. Metab. Disord., 2001, 25, 748-752.
20. Tan, C.E.; Ma, S.; Wai, D.; Chew, S.K.; Tai, E.S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care, 2004, 27, 1182-1186.
21. Thomas, G.N.; Ho, S.Y.; Janus, E.D.; Lam, K.S.; Hedley, A.J.; Lam, T.H.; Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes Res. Clin. Pract., 2005, 67, 251-257.
22. Ko, G.T.; Cockram, C.S.; Chow, C.C..; Yeung, V.T.; Chan, W.B.; So, W.Y.; Chan, N.N.; Chan, J.C. Metabolic syndrome by the international diabetes federation definition in Hong Kong Chinese. Diabetes Res Clin Pract., 2006, 73, 58-64.
23. Heng,D.; Ma, S.; Lee, J.J.; Tai, B.C..; Mak, K.H.; Hughes, K.; Chew, S.K.; Chia, K.S.; Tan, C.E.; Tai, E.S. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis, 2006, 186, 367-373.
24. Carr, M.C.; Brunzell, J.D. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J. Clin. Endocrinol. Metab., 2004, 89, 2601-2607.
25. Chaisiri, K.; Pongpaew, P.; Tungtrongchitr, R.; Phonrat, B.; Kulleap, S.; Sutthiwong, P.; Intarakhao, C.; Mahaweerawat, U.; Khongdee, W.; Sanchaisuriya, P.; Saowakontha, S.; Merkle, A.; Schelp, F.P. Nutritional status and serum lipids of a rural population in Northeast Thailand - an example of health transition. Int. J. Vitam. Nutr. Res., 1998, 68, 196-202.
26. Nielsen, S.; Guo, Z.; Johnson, C.M.; Hensrud, D.D.; Jensen, M.D. Splanchnic lipolysis in human obesity. J. Clin. Invest. 2004, 113, 1582-1588.
27. Lewis, G.F.; Carpentier, A.; Adeli, K.; Giacca, A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev., 2002, 23, 201-229.
28. Taghibiglou, C.; Carpentier, A.; Van Iderstine, S.C.; Chen, B.; Rudy, D.; Aiton A.; Lewis, G.F.; Adeli, K. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J. Biol. Chem., 2000, 275, 8416-8425.
29. Tan, C.E.; Foster, L.; Caslake, M.J.; Bedford, D.; Watson, T.D.; McConnell, M.; Packard, C.J.; Shepherd, J. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1839-1848.
30. Chirieac, D.V.; Chirieac, L.R.; Corsetti, J.P.; Cianci, J.; Sparks, C.E.; Sparks, J.D. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am. J. Physiol. Endocrinol. Metab. 2000, 279, E1003-1011.
31. Malmstrom, R.; Packard, C.J.; Watson, T.D.; Rannikko, S.; Caslake, M.; Bedford, D.; Stewart, P.; Yki-Jarvinen, H.; Shepherd, J.; Taskinen, M.R. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 1454-1464.
32. Adiels. M.; Boren, J.; Caslake, M.J.; Stewart, P.; Soro, A.; Westerbacka, J.; Wennberg, B.; Olofsson, S.O.; Packard, C.; Taskinen, M.R. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1697-703.
33. Foufelle, F.; Ferre, P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem. J., 2002, 366, (Pt 2):377-391.
34. Matsumoto, M.; Ogawa, W.; Teshigawara, K.; Inoue, H.; Miyake, K.; Sakaue, H.; Kasuga, M. Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes. Diabetes, 2002, 51, 1672-1680.
35. Zhou, X.Y.; Shibusawa, N.; Naik, K.; Porras, D.; Temple, K.; Ou, H.; Kaihara, K.; Roe, M.W.; Brady, M.J.; Wondisford, F.E. Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Nat. Med., 2004, 10, 633-637.
36. Iizuka, K.; Bruick, R.K.; Liang, G.; Horton, J.D.; Uyeda, K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. USA, 2004, 101, 7281-7286.
37. Browning, J.D.; Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest., 2004, 114, 147-152.
38. Phung, T.L.; Roncone, A.; Jensen, K.L.; Sparks, C.E.; Sparks, J.D. Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J. Biol. Chem., 1997, 272, 30693-30702.
39. Kuriyama, H.; Yamashita, S.; Shimomura, I.; Funahashi, T.; Ishigami, M.; Aragane, K.; Miyaoka, K.; Nakamura, T.; Takemura, K.; Man, Z.; Toide, K.; Nakayama, N.; Fukuda, Y.; Lin, M.C.; Wetterau, J.R.; Matsuzawa, Y. Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. Hepatology, 1998, 27, 557-562.
40. Bartels, E.D.; Lauritsen, M.; Nielsen, L.B. Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. Diabetes, 2002, 51, 1233-1239.
41. Carpentier, A.; Taghibiglou, C.; Leung, N.; Szeto, L.; Van Iderstine, S.C.; Uffelman, K.D.; Buckingham, R.; Adeli, K.; Lewis, G.F. Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J. Biol. Chem., 2002, 277, 28795-28802.
42. Goldberg, I.J. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res., 1996, 37, 693-707.
43. Karpe, F.; Olivecrona, T.; Hamsten, A.; Hultin, M. Chylomicron/ chylomicron remnant turnover in humans: evidence for margination of chylomicrons and poor conversion of larger to smaller chylomicron remnants. J. Lipid Res., 1997, 38, 949-961.
44. Goldberg, I.J.; Kako, Y.; Lutz, E.P. Responses to eating: lipoproteins, lipolytic products and atherosclerosis. Curr. Opin. Lipidol., 2000, 11, 235-241.
45. Taskinen, M.R. Lipoprotein lipase in diabetes. Diabetes Metab. Rev., 1987, 3, 551-570.
46. Panarotto, D.; Remillard, P.; Bouffard, L.; Maheux, P. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur. J. Clin. Invest., 2002, 32, 84-92.
47. Haidari, M.; Leung, N..; Mahbub, F.; Uffelman, K.D.; Kohen-Avramoglu, R.; Lewis, G.F.; Adeli, K. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J. Biol. Chem., 2002, 277, 31646-31655.
48. Lamarche, B.; Rashid, S.; Lewis, G.F. HDL metabolism in hypertriglyceridemic states: an overview. Clin. Chim. Acta, 1999, 286, 145-161.
49. Pascot, A.; Lemieux, I.; Prud'homme, D.; Tremblay, A.; Nadeau, A.; Couillard, C.; Bergeron, J.; Lamarche, B.; Despres, J.P. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J. Lipid. Res., 2001, 42, 2007-2014.
50. Inazu, A.; Koizumi, J.; Mabuchi, H. Cholesteryl ester transfer protein and atherosclerosis. Curr. Opin. Lipidol., 2000, 11, 389-396.
51. Santamarina-Fojo, S.; Haudenschild, C.; Amar, M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr. Opin. Lipidol., 1998, 9, 211-219.
52. Rashid, S.; Barrett, P.H.; Uffelman, K.D.; Watanabe, T.; Adeli, K.; Lewis, G.F. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 483-487.
53. Pietzsch, J.; Julius, U.; Nitzsche, S.; Hanefeld, M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes, 1998, 47, 1928-1934.
54. Ji. J.; Watts, G.F.; Johnson, A.G.; Chan, D.C.; Ooi, E.M.; Rye, K.A.; Serone, A.P.; Barrett, P.H. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J. Clin. Endocrinol. Metab., 2006, 91, 973-979.
55. Sviridov, D.; Nestel, P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis, 2002, 161, 245-254.
56. Wang, N.; Tall, A.R. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 1178-1184.
57. Tu, A.Y.; Albers, J.J. Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes, 2001, 50, 1851-1856.
58. Alenezi, M.Y.; Marcil, M.; Blank, D.; Sherman, M.; Genest, J. Jr. Is the decreased high-density lipoprotein cholesterol in the metabolic syndrome due to cellular lipid efflux defect? J. Clin. Endocrinol. Metab., 2004, 89, 761-764.
59. Schaefer, E.J.; McNamara, J.R.; Shah, P.K.; Nakajima, K.; Cupples, L.A.; Ordovas, J.M.; Wilson, P.W.; Framingham Offspring Study. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care, 2002, 25, 989-994.
60. Hurt-Camejo, E.; Camejo, G.; Sartipy, P. Phospholipase A2 and small, dense low-density lipoprotein. Curr. Opin. Lipidol., 2000, 11, 465-471.
61. Boren, J.; Lee, I.; Zhu, W.; Arnold, K.; Taylor, S.; Innerarity, T.L. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J. Clin. Invest., 1998, 101, 1084-1093.
62. Tchernof, A.; Lamarche, B.; Prud'Homme, D.; Nadeau, A.; Moorjani, S.; Labrie, F.; Lupien, P.J.; Despres, J.P. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care, 1996, 19, 629-637.
63. Gray, R.S.; Robbins, D.C.; Wang, W.; Yeh, J.L.; Fabsitz, R.R.; Cowan, L.D.; Welty, T.K.; Lee, E.T.; Krauss, R.M.; Howard, B.V. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 2713-2720.
64. Ambrosch, A.; Muhlen, I.; Kopf, D.; Augustin, W.; Dierkes, J.; Konig, W.; Luley, C.; Lehnert, H. LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects. Diabetes Care, 1998, 21, 2077-2084.
65. Packard, C.J.; Demant, T.; Stewart, J.P.; Bedford, D.; Caslake, M.J.; Schwertfeger, G.; Bedynek, A.; Shepherd, J.; Seidel, D. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J. Lipid Res., 2000, 41, 305-318.
66. Tan, K.C.; Shiu, S.W.; Chu, B.Y. Roles of hepatic lipase and cholesteryl ester transfer protein in determining low density lipoprotein subfraction distribution in Chinese patients with non-insulin-dependent diabetes mellitus. Atherosclerosis, 1999, 145, 273-278.
67. Chapman, M.J.; Guerin, M.; Bruckert, E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur. Heart J., 1998, 19 Suppl A, A24-30.
68. Anber, V.; Griffin, B.A.; McConnell, M.; Packard, C.J.; Shepherd, J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis, 1996, 124, 261-271.
69. Galeano, N.F.; Al-Haideri, M.; Keyserman, F.; Rumsey, S.C.; Deckelbaum, R.J. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J. Lipid Res., 1998, 39, 1263-1273.
70. Tribble, D.L.; Holl, L.G.; Wood, P.D.; Krauss, R.M. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis, 1992, 93, 189-199.
71. Chancharme, L.; Therond, P.; Nigon, F.; Lepage, S.; Couturier, M.; Chapman, M.J. Cholesteryl ester hydroperoxide lability is a key feature of the oxidative susceptibility of small, dense LDL. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 810-820.
72. Tuomilehto, J.; Lindstrom, J.; Eriksson, J.; Valle, T.; Hamalainen, T.; Ilanne-Parikka, P.; Keinanen-Kiukaanniemi, S.; Laakso, M.; Louheranta, A.; Rastas, M.; Salminen, V.; Uusitupa, M.; Aunola, S.; Cepaitis, Z.; Moltchanov, V.; Hakumaki, M.; Mannelin, M.; Martikkala, V. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med., 2001, 344, 1343-1350.
73. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 2002, 346, 393-403.
74. Milani, R.V.; Lavie, C.J. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation. Am. J. Cardiol., 2003, 92, 50-54.
75. Chan, D.C.; Barrett, H.P.; Watts, G.F. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am. J. Cardiovasc. Drugs, 2004, 4, 227-246.
76. Sacks, F.M.; Katan, M. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. Am. J. Med., 2002, 113(Suppl. 9B), 13S-24S.
77. Knopp, R.H.; Retzlaff, B.; Walden, C.; Fish, B.; Buck, B.; McCann, B. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects. Proc. Soc. Exp. Biol. Med., 2000, 225, 191-199.
78. Deedwania, P.C.; Hunninghake, D.B.; Bays, H.E.; Jones, P.H.; Cain, V.A.; Blasetto, J.W. STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am. J. Cardiol., 2005, 95, 360-366.
79. Stalenhoef, A.F.; Ballantyne, C.M.; Sarti, C.; Murin, J.; Tonstad, S.; Rose, H.; Wilpshaar, W. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur. Heart J., 2005, 26, 2664-2672.
80. Clearfield, M.; Downs, J.R.; Lee, M.; Langendorfer, A.; McConathy, W.; Gotto, A.M. Jr. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines Am. J. Cardiol., 2005, 96, 1674-1680.
81. Sattar, N.; Gaw, A.; Scherbakova, O.; Ford, I.; O'Reilly, D.S.; Haffner, S.M.; Isles, C.; Macfarlane, P.W.; Packard, C.J.; Cobbe, S.M.; Shepherd, J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 2003, 108, 414-419.
82. Pyorala, K.; Ballantyne, C.M.; Gumbiner, B.; Lee, M.W.; Shah, A.; Davies, M.J.; Mitchel, Y.B.; Pedersen, T.R.; Kjekshus, J.; Scandinavian Simvastatin Survival Study (4S). Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care, 2004, 27, 1735-1740.
83. Geluk, C.A.; Asselbergs, F.W.; Hillege, H.L.; Bakker, S.J.; de Jong, P.E.; Zijlstra, F.; van Gilst, W.H. Impact of statins in micro-albuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur. Heart J., 2005, 26, 1314-1320.
84. Sever, P.S.; Dahlof, B.; Poulter, N.R.; Wedel, H.; Beevers, G.; Caulfield, M.; Collins, R.; Kjeldsen, S.E.; Kristinsson, A.; McInnes, G.T.; Mehlsen, J.; Nieminen, M.; O'Brien, E.; Ostergren, J.; ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003, 361, 1149-1158.
85. Fruchart, J.C.; Duriez, P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006, 42, 39-64.
86. Tenkanen, L.; Manttari, M.; Manninen, V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation, 1995, 92, 1779-1785.
87. Robins, S.J.; Rubins, H.B.; Faas, F.H.; Schaefer, E.J.; Elam, M.B.; Anderson, J.W.; Collins, D.; Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care, 2003, 26, 1513-1517.
88. Tenenbaum, A.; Motro, M.; Fisman, E.Z.; Tanne, D.; Boyko, V.; Behar, S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med., 2005, 165, 1154-1160.
89. Keech, A.; Simes, R.J.; Barter, P.; Best, J.; Scott, R.; Taskinen, M.R.; Forder, P.; Pillai, A.; Davis, T.; Glasziou, P.; Drury, P.; Kesaniemi, Y.A.; Sullivan, D.; Hunt, D.; Colman, P.; d'Emden, M.; Whiting, M.; Ehnholm, C.; Laakso, M.; FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005, 366, 1849-1861.
90. Lorenzen, A.; Stannek, C.; Lang, H.; Andrianov, V.; Kalvinsh, I.; Schwabe, U. Characterization of a G protein-coupled receptor for nicotinic acid. Mol. Pharmacol. 2001, 59, 349-357.
91. Karpe, F.; Frayn, K.N. The nicotinic acid receptor - a new mechanism for an old drug. Lancet, 2004, 363, 1892-1894.
92. Rubic, T.; Trottmann, M.; Lorenz, R.L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmacol., 2004, 67, 411-119.
93. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA, 1975, 231, 360-381.
94. Carlson, L.A.; Rosenhamer, G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta. Med. Scand. 1988, 223, 405-418.
95. Zhao, X.Q.; Morse, J.S.; Dowdy, A.A.; Heise, N.; DeAngelis, D.; Frohlich, J.; Chait, A.; Albers, J.J.; Brown, B.G. Simvastatin plus niacin protect against atherosclerosis porgession and clinical events in coronary artery disease patients with metabolic syndrome. J. Am. Coll. Cardiol., 2002, 29(Suppl A), 242A {abstract}
96. Canner, P.L.; Furberg, C.D.; McGovern, M.E. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol., 2006, 97, 477-449.
97. Elam, M.B.; Hunninghake, D.B.; Davis, K.B.; Garg, R.; Johnson, C.; Egan, D.; Kostis, J.B.; Sheps, D.S.; Brinton, E.A. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA, 2000, 284, 1263-1270.
98. Grundy, S.M.; Vega, G.L.; McGovern, M.E.; Tulloch, B.R.; Kendall, D.M.; Fitz-Patrick, D.; Ganda, O.P.; Rosenson, R.S.; Buse, J.B.; Robertson, D.D.; Sheehan, J.P.; Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med., 2002, 162, 1568-1576.
99. Yatskar, L.; Fisher, E.A.; Schwartzbard, A. Ezetimibe: rationale and role in the management of hypercholesterolemia. Clin. Cardiol., 2006, 29, 52-55.
100. Garcia-Calvo, M.; Lisnock, J.; Bull, H.G.; Hawes, B.E.; Burnett, D.A.; Braun, M.P.; Crona, J.H.; Davis, H.R. Jr, Dean, D.C.; Detmers, P.A.; Graziano, M.P.; Hughes, M.; Macintyre, D.E.; Ogawa, A.; O'neill, K.A.; Iyer, S.P.; Shevell, D.E.; Smith, M.M.; Tang, Y.S.; Makarewicz, A.M.; Ujjainwalla, F.; Altmann, S.W.; Chapman, K.T.; Thornberry, N.A. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA, 2005, 102, 8132-8137.
101. Bays, H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am. J. Cardiol., 2006, 98, 71i-76i.
102. Carpentier, Y.A.; Portois, L.; Malaisse, W.J. n-3 fatty acids and the metabolic syndrome. Am. J. Clin Nutr., 2006, 83(6 Suppl), 1499S-1504S.
103. Robinson, J.G.; Stone, N.J. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am. J. Cardiol., 2006, 98(4A), 39i-49i.
104. Okamoto, H.; Yonemori, F.; Wakitani, K.; Minowa, T.; Maeda, K.; Shinkai, H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature, 2000, 406, 203-207.
105. de Grooth, G.J.; Kuivenhoven, J.A.; Stalenhoef, A.F, de Graaf, J.; Zwinderman, A.H.; Posma, J.L.; van Tol, A.; Kastelein, J.J. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation, 2002, 105, 2159-2165.
106. Clark, R.W.; Sutfin, T.A.; Ruggeri, R.B.; Willauer, A.T.; Sugarman, E.D.; Magnus-Aryitey, G.; Cosgrove, P.G.; Sand, T.M.; Wester, R.T.; Williams, J.A.; Perlman, M.E.; Bamberger, M.J. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 490-497
107. Prueksaritanont, T.; Zhao, J.J.; Ma, B.; Roadcap, B.A.; Tang, C.; Qiu, Y.; Liu, L.; Lin, J.H.; Pearson, P.G.; Baillie, T.A. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther., 2002, 301, 1042-1051.
108. Vega, G.L.; Ma, P.T.; Cater, N.B.; Filipchuk, N.; Meguro, S.; Garcia-Garcia, A.B.; Grundy, S.M. Effects of adding fenofibrate (200 mg/ day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am. J. Cardiol., 2003, 91, 956-960.
109. Athyros, V.G.; Mikhailidis, D.P.; Papageorgiou, A.A.; Didangelos, T.P.; Peletidou, A.; Kleta, D.; Karagiannis, A.; Kakafika, A.I.; Tziomalos, K.; Elisaf, M. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism, 2005, 54, 1065-1074.
110. Wierzbicki, A.S.; Mikhailidis, D.P.; Wray, R.; Schacter, M.; Cramb, R.; Simpson, W.G.; Byrne, C.B. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr. Med. Res. Opin., 2003, 19, 155-168.
111. Nambi, V.; Ballantyne, C.M. Combination therapy with statins and omega-3 fatty acids. Am. J. Cardiol., 2006, 98(4A), 34i-38i.
112. Taylor, A.J.; Sullenberger, L.E.; Lee, H.J.; Lee, J.K.; Grace, K.A.. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation, 2004, 110, 3512-3517.
113. Simons, L.; Tonkon, M.; Masana, L.; Maccubbin, D.; Shah, A.; Lee, M.; Gumbiner, B. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr. Med. Res. Opin., 2004, 20, 1437-1445.